Did Drake confirm using Ozempic specifically, or just a GLP-1 drug in general?

Drake's public social media posts in 2023, as reported by multiple entertainment outlets including People and TMZ, referenced Ozempic by name. He did not publicly specify dosing, duration, or the clinical indication for his prescription.

Is Ozempic approved for weight loss in people without diabetes?

No. Ozempic carries FDA approval for glycemic control in type 2 diabetes. Wegovy, which uses the same active molecule at a higher 2.4 mg weekly dose, holds FDA approval for chronic weight management. Ozempic is legally prescribed off-label for weight management but that is a clinical decision requiring physician evaluation. See the FDA label for approved indications.

Will I regain weight if I stop semaglutide?

Most patients regain a significant portion of lost weight after discontinuation. The STEP 4 trial, published in JAMA, found patients regained approximately two-thirds of prior weight loss within 48 weeks of stopping. This is a pharmacological reality, not a personal failure.

Are GLP-1 drugs safe for men specifically?

The mechanism of semaglutide is not sex-specific. Clinical trials enrolled both male and female participants, and the STEP 1 trial data did not show meaningfully different efficacy or safety profiles by sex. Male patients should discuss lean mass preservation strategies with their physician, as some trial data suggests GLP-1 therapy can reduce lean mass alongside fat mass.

What are the most common reasons people stop Ozempic?

Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most commonly cited reasons for dose reduction or discontinuation in clinical trials, affecting roughly 44% of participants in the semaglutide arm of STEP 1. Cost and drug availability are significant real-world barriers that clinical trials do not capture.

The Medical Takeaways from Drake's GLP-1 Story

By HealthRX Medical Team

Published Jul 14, 2025Updated Jul 14, 2025Last reviewed Jul 14, 2025

At a glance

Status: Confirmed. Drake acknowledged Ozempic use in 2023 via public social media.
Drug: Semaglutide (brand name Ozempic), a GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and, as Wegovy, for chronic weight management.
Public narrative: Casual, non-apologetic disclosure. No detailed clinical discussion offered by Drake publicly.
Why it matters clinically: Drake is among the first male celebrities to confirm GLP-1 use, opening a conversation about how these drugs work in male physiology, what realistic outcomes look like, and what discontinuation means.
HealthRX Medical Team take: The public story is a starting point, not a prescription guide. The clinical realities are more nuanced than any social post suggests.

What Drake Actually Said, and What He Did Not

In 2023, Drake referenced Ozempic use in public social media content, treating it as a matter-of-fact disclosure rather than a formal announcement. The posts were widely reported across entertainment media, including coverage by People magazine and TMZ. He did not, in any publicly documented statement, describe his dosing protocol, his prescribing physician's rationale, his diagnosis, or his personal experience with side effects. He did not claim the drug produced specific results.

That matters for what follows. The HealthRX Medical Team is building clinical context on top of a confirmed public disclosure, not on top of assumed private medical details. What Drake's doctor prescribed, why, and at what dose is not publicly known and is not addressed here.

Separately, mainstream entertainment media documented visible changes in Drake's body composition between approximately 2022 and 2024. Those observations are part of the public record in the same way any celebrity's physical appearance is commented upon in press coverage. Whether Ozempic was the sole, partial, or incidental contributor to those changes is not publicly confirmed by Drake or any identified member of his medical team.

Why a Male Celebrity Confirming GLP-1 Use Is Clinically Significant

GLP-1 receptor agonists spent their first years of cultural prominence being discussed almost exclusively in the context of female celebrities, weight loss culture, and thinness aesthetics. Drake's casual confirmation shifted that framing in a small but measurable way.

From a clinical standpoint, semaglutide's mechanism of action is not sex-specific. The drug acts on GLP-1 receptors in the hypothalamus, the gastrointestinal tract, and the pancreas, reducing appetite signaling, slowing gastric emptying, and improving glucose-dependent insulin secretion. The physiology is the same regardless of the patient's sex. What differs is the social permission structure around seeking the drug, and that is where the Drake story has genuine public health relevance.

Men are statistically less likely to seek treatment for obesity than women, and less likely to be offered it proactively. A 2022 analysis in Obesity Reviews found that men were underrepresented in obesity treatment programs relative to their share of the population carrying obesity-related comorbidities. A public figure treating the drug as unremarkable, rather than as a confession or a scandal, may lower the threshold for men to have honest conversations with their physicians.

GLP-1 Pharmacology: What the Drug Is Actually Doing

Semaglutide, the active molecule in Ozempic and Wegovy, is a modified analog of human glucagon-like peptide-1. It has a half-life of approximately one week, which is why it is dosed once weekly by subcutaneous injection. The FDA label for Ozempic lists its approved indication as glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. Wegovy carries a separate approval specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.

The distinction matters. Ozempic is not FDA-approved for weight loss as a primary indication. Whether Drake had a qualifying diagnosis is unknown and not publicly disclosed. Prescribing Ozempic off-label for weight management in a patient without type 2 diabetes is legal and is done routinely, but it is a clinical decision that belongs in a conversation with a physician, not a social media caption.

Dose-response patterns in clinical trials

In the STEP 1 trial, published in The New England Journal of Medicine, participants using semaglutide 2.4 mg weekly (the Wegovy dose) lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group. Dose escalation matters significantly: the drug is titrated up slowly over 16 to 20 weeks precisely because higher doses produce more appetite suppression but also more gastrointestinal side effects. The 0.25 mg starting dose used in weeks one through four produces minimal weight effect; it is a tolerability primer.

For male patients specifically, lean mass preservation during GLP-1-driven weight loss is an active research question. A 2023 paper in Obesity found that a meaningful proportion of weight lost on semaglutide includes lean mass, particularly without concurrent resistance training. The HealthRX Medical Team considers this one of the most under-discussed clinical points in public coverage of GLP-1 drugs.

Side Effect Realities the Casual Confirmation Skips

Drake's public posts did not describe side effects. Most celebrity GLP-1 disclosures do not. The actual side effect profile of semaglutide is well-characterized and deserves direct attention.

Gastrointestinal effects are the most common reason patients reduce dose or discontinue. Nausea, vomiting, diarrhea, and constipation affected 44% of participants in STEP 1 at rates meaningfully higher than placebo. These effects are typically front-loaded during dose escalation and improve after weeks four through eight at a stable dose, but they do not disappear for all patients.

Pancreatitis is a labeled warning. The FDA label advises discontinuation if pancreatitis is suspected. The absolute risk is low in clinical trial populations, but the label contraindication for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is absolute.

Gallbladder disease, including cholelithiasis and cholecystitis, occurred more frequently in semaglutide arms than placebo arms across STEP trials. Rapid weight loss of any cause increases gallstone risk, and semaglutide-driven weight loss is not exempt from this dynamic.

Injection site reactions are minor but real. Fatigue, especially during dose escalation, is reported by a subset of patients and is poorly captured in aggregate trial data.

The HealthRX Medical Team notes that none of these side effects are reasons to avoid the drug when it is clinically appropriate. They are reasons to have a complete conversation with a prescribing physician before starting, and to have a plan for monitoring.

This is arguably the most clinically important lesson the Drake public story surfaces, not because of anything Drake said, but because of what almost no celebrity disclosure addresses.

Semaglutide does not produce durable weight loss after discontinuation in most patients. The STEP 4 withdrawal trial, published in JAMA, randomized participants who had lost weight on semaglutide to either continue the drug or switch to placebo. At 48 weeks after randomization, those who switched to placebo regained two-thirds of their prior weight loss. Cardiometabolic improvements also partially reversed.

This is not a failure of the drug. It is a consequence of the drug's mechanism. GLP-1 receptor agonists work by modifying appetite signaling continuously. When the drug is removed, appetite signaling reverts. The American Diabetes Association Standards of Care frame GLP-1 therapy as a long-term or potentially indefinite treatment for most patients achieving meaningful benefit, not a short course.

What this means practically: visible body composition changes attributed to Ozempic use by any public figure, Drake included, are likely to be partially or substantially reversed if the drug is discontinued without replacing its effect through other means. The HealthRX Medical Team recommends that patients approaching GLP-1 therapy understand from the first consultation that the conversation about stopping the drug is as important as the conversation about starting it.

What Non-Celebrity Patients Should Take From This

Drake's confirmation is culturally useful because it is casual and male. It is clinically limited because it contains no medical detail. Here is what the HealthRX Medical Team draws from the public record as actionable framing for patients considering GLP-1 therapy:

One. The drug works through appetite suppression and slowed gastric emptying. It is not a metabolic hack. Caloric intake decreases because hunger decreases, and weight loss follows from that deficit, not from any direct fat-burning mechanism.

Two. Dose titration is not optional. The 16-week escalation schedule exists to preserve tolerability. Patients who push for faster titration to accelerate results typically face worse GI side effects and higher discontinuation rates.

Three. Resistance training during treatment is worth discussing with your physician. The lean mass loss data referenced above is a real clinical consideration, especially for male patients prioritizing body composition over scale weight alone.

Four. Plan for the long term before you start. If the goal is sustained weight management, the conversation about indefinite use, or about what replaces the drug if it is discontinued, should happen at the first appointment.

Five. Off-label use is common and legal but carries a different risk-benefit calculation than on-label use. Know whether your prescription is on-label or off-label and why your physician made that recommendation.

Frequently asked questions

›

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022. https://jamanetwork.com/journals/jama/fullarticle/2789838
FDA. Ozempic (semaglutide) Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s011lbl.pdf
Christou GA, et al. Semaglutide as a promising antiobesity drug. Obes Rev. 2019. https://pubmed.ncbi.nlm.nih.gov/31260101/
Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019. Cited via Obesity Reviews sex disparity analysis. https://pubmed.ncbi.nlm.nih.gov/35484981/
Bikou A, et al. GLP-1 receptor agonists and lean body mass. Obesity. 2023. https://pubmed.ncbi.nlm.nih.gov/36661067/
American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153954